Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs

Angela Liu, Leonard Naymagon, Douglas Tremblay

Research output: Contribution to journalReview articlepeer-review

Abstract

Patients who develop splanchnic vein thrombosis (SVT) in the setting of a myeloproliferative neoplasm (MPN) are at risk for complications including portal hypertension, bleeding, thrombosis, and death. Prompt multidisciplinary treatment is thus necessary to prevent long-term sequelae. However, optimal management strategies are not well established due to a paucity of data. In this review, we very briefly discuss the epidemiology, pathophysiology, and prognosis of MPN-SVT and then more comprehensively explore treatment considerations of MPN-SVT, including anticoagulation, endovascular/surgical intervention, and cytoreductive therapy. We will also highlight current gaps in our knowledge of MPN-SVT and conclude by suggesting future directions to optimize the treatment of MPN-SVT and improve outcomes.

Original languageEnglish
Article number11
JournalCancers
Volume15
Issue number1
DOIs
StatePublished - Jan 2023

Keywords

  • essential thrombocythemia
  • myelofibrosis
  • myeloproliferative
  • polycythemia vera
  • splanchnic vein
  • thrombosis

Fingerprint

Dive into the research topics of 'Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs'. Together they form a unique fingerprint.

Cite this